What question did this study set out to answer?

To assess the association between Medicare insurance type and receipt of optimal cancer treatment and associated costs.

Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study assesses treatment quality and cost differences between Medicare plans, suggesting cost advantages for Medicare Advantage.

To assess the association between Medicare insurance type and receipt of optimal cancer treatment and associated costs.
Retrospective cohort study using Medicare claims data from 2015-2019.
Included beneficiaries aged 74 on average with incident cancer diagnoses and treatment scenarios.
Analyzed treatment receipt and costs linked to National Comprehensive Cancer Network Guidelines.
Of 35,245 patients: 24,269 in Traditional Medicare (TM) and 10,976 in Medicare Advantage (MA) with similar optimal treatment likelihood (adjusted RR 0.99, 95% CI 0.97-1.02).
MA had lower mean treatment costs ($29,252) compared to TM ($40,874), indicating a cost ratio of 0.94 (95% CI 0.91-0.97).
Average savings for MA beneficiaries was -$931 (95% CI -$1244 to -$615).

Mitchell et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort study assesses treatment quality and cost differences between Medicare plans, suggesting cost advantages for Medicare Advantage.